BE1000147A3 - Topical compositions antiinflammatory. - Google Patents

Topical compositions antiinflammatory. Download PDF

Info

Publication number
BE1000147A3
BE1000147A3 BE8700208A BE8700208A BE1000147A3 BE 1000147 A3 BE1000147 A3 BE 1000147A3 BE 8700208 A BE8700208 A BE 8700208A BE 8700208 A BE8700208 A BE 8700208A BE 1000147 A3 BE1000147 A3 BE 1000147A3
Authority
BE
Belgium
Prior art keywords
excipients
topical compositions
acemetacin
active principle
compositions
Prior art date
Application number
BE8700208A
Other languages
French (fr)
Inventor
Maria Alessandra Tonozzi
Lucia Mazzoni
Original Assignee
Ibis Ist Biochim Speriment
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ibis Ist Biochim Speriment filed Critical Ibis Ist Biochim Speriment
Application granted granted Critical
Publication of BE1000147A3 publication Critical patent/BE1000147A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Compositions pharmaceutiques topiques contenant de l'acémétacine comme principe actif, ces compositions étant intéressantes dans le traitement d'états phlogistiques ou inflammatoires en divers endroits du corps humain.Topical pharmaceutical compositions containing acemetacin as active ingredient, these compositions being advantageous in the treatment of phlogistic or inflammatory states in various places of the human body.

Description

       

   <Desc/Clms Page number 1> 
 



    "Composittons anti-inflammatoires topiques".    



   La présente invention se rapporte à des compositions anti-inflammatoires topiques, contenant, comme principe actif, fester   carboxyméthylique   de l'acide 1-(4-chlorobenzoyl)-5-méthoxy-2-méthyl-   IH-indole-3-acétique, connu également   sous le nom   d'acémétacine.   



     L'acemetacine decrite dans) e   brevet allemand   ne 2. 234. 651   est un agent anti-inflammatoire connu, déjà utilisé en thérapeutique humaine pour ses propriétés pharmacologiques (Arzn. 



  Forsch. 30,   1398, 1980).   
 EMI1.1 
 



  L'unique voie d'administration considérée jusqutà présent a été la voie orale. On a maintenant constaté que tion dlacémétacine par voie topique dermatologique, sous la forme de pommades, de crèmes, de gels, de pâtes, est bien tolérée et permet d'obtenir des effets thérapeutiques avantageux dans le secteur de pathologies, telles que la polyarthrite chronique évolutive, les affections inflammatoires de diverses localisations   (tendinites, tenosynovites, bursites, thrombophtebites, distorsions,    hématomes, myalgies, lombalgics, périarthrites, contusions, déchirures musculaires, oedèmes et tissus infiltrés traumatiques). 



   On a en particulier constaté que l'emploi local est extrêmement avantageux par rapport à la forme orale, avec une incidence nettement inférieure des effets collatéraux. En outre, les concentrations de principe actif dans le liquide synovial sont   particuliè-   rement élevées et sont rapidement atteintes après une administration topique. 



   Les compositions topiques   faisant l'objet   de la présente invention peuvent contenir le principe actif en une quantité comprise entre 0, 5 et 5 % en poids, de préférence entre   1   % et 3   %   en poids, 

 <Desc/Clms Page number 2> 

 
 EMI2.1 
 ce principe actif étant convenablement formulé en utilisant des véhicules ou des excipients Des exemples de véhicules et excipients de ce genre sont les excipients huileux, tels que les graisses, les huites végétales, le beurre de cacao, la cire de carnauba, le spermacéti, la vaseline, les silicones excipients d'absorption, tels gras supérieurs des excipients émulsionnant et/ou hydrosolubles, tels que la glycérine, le glycol propylénique, le polyéthylène glycol, des dérivés de la cellulose, la gomme adragante, la pectine, outre des agents antibactériens,

   des agents de conservation, des parfums, des essences,    etc.   



   Le choix des excipients sera effectue sur la base du type désiré de formulation, d'après les connaissances normalernent disponibles, teiles que signalées, par exemple, dans"Remington's Pharmaceutical Sciences Handbook", Hack Publishing Co.,   U. S. A..   



   11 est en outre évident que diverses autres substances 
 EMI2.2 
 peuvent etre employées en plus ou à la place de celles indiquées ci-dessus, et ce comme le savent les spécialistes dans ce domaine pharmaceutique. 11 doit etre entendu que toutes ces formulations, bien que n'étant pas décrites de   facon particulière,   restent normalement dans le cadre de la présente invention. En outre, la préparation des compositions citées ci-dessus est menée suivant les techniques connues de l'art, par exemple par incorporation mécanique du principe actif 
 EMI2.3 
 dans la base des excipients, par fusion, émulsionnement, etc.

   Les compositions faisant l'objet de l'invention peuvent. éventuellement contenir d'autres principes actifs, présentant une activité   complêmen-   taire ou utile d'une façon générale, tels que des antiseptiques, des analgésiques, des   héparínoides,   etc. 



   Les Exemples suivants illustrent encore t'invention sans pour autant limiter celle-ci d'une manière quelconque. 

 <Desc/Clms Page number 3> 

 
 EMI3.1 
 



  EXEMPLE Crème à 2 % Composition 100 g de crème contiennent : 
 EMI3.2 
 Aeémétacine 2 g Excipients : Esters polyglycoliques d'acides gras 18 g Glycol propylénique 7 g Alcool cétostéarylique 3, 5 g Polyéthylène glycol 1000, monocétyl éther 2 g 
 EMI3.3 
 Alcool phényléthy1íque g 
0, 5Citrate de sodium   0, 402 g   Acide citrique monohydraté 0, 28 g Parfum anallergique 0, 1 g Eau pure, quantité suffisante pour faire 100 g EXEMPLE 2 
 EMI3.4 
 Gel à 2 % Composition Acémétacine 2 g Excipients:

   Carbopol 940 0, g Triéthanolamine 1, OS g 
8Glycérine 2 g Isopropanol 30 g Huile de coprah 0, 04 g Huile de lavande 0, 04 g Eau de Cologne 0, 07 g Eau   déminéralisee,   quantité suffisante pour faire 100 g 

 <Desc/Clms Page number 4> 

 
 EMI4.1 
 EXEMPLE Gel Composition Acemetacine 2 g Excipients Carboxypolyméthylène 2 g p-Hydroxybenzoate de méthyle 0, g p-Hydroxybenzoate de propyle g Essence de neroli 0, g Essence de lavande 0, g Alcool 10 ml Eau déminéralisée, quantité suffisante pour faire 100 g.



   <Desc / Clms Page number 1>
 



    "Topical anti-inflammatory compositions".



   The present invention relates to topical anti-inflammatory compositions containing, as active principle, carboxymethyl ester of 1- (4-chlorobenzoyl) -5-methoxy-2-methyl-IH-indole-3-acetic acid, known also under the name of acemetacin.



     Acemetacin described in the German patent no. 2,334,651 is a known anti-inflammatory agent, already used in human therapy for its pharmacological properties (Arzn.



  Forsch. 30, 1398, 1980).
 EMI1.1
 



  The only route of administration considered so far has been the oral route. It has now been found that the application of acemetacin topically dermatologically, in the form of ointments, creams, gels, pastes, is well tolerated and makes it possible to obtain advantageous therapeutic effects in the sector of pathologies, such as chronic polyarthritis. active, inflammatory conditions of various localizations (tendinitis, tenosynovitis, bursitis, thrombophtebitis, distortions, hematomas, myalgia, low back pain, periarthritis, bruising, muscle tears, edema and traumatic infiltrated tissue).



   In particular, it has been found that local use is extremely advantageous compared to the oral form, with a much lower incidence of collateral effects. In addition, the concentrations of active ingredient in the synovial fluid are particularly high and are quickly reached after topical administration.



   The topical compositions which are the subject of the present invention may contain the active principle in an amount of between 0.5 and 5% by weight, preferably between 1% and 3% by weight,

 <Desc / Clms Page number 2>

 
 EMI2.1
 this active principle being suitably formulated using vehicles or excipients Examples of vehicles and excipients of this kind are oily excipients, such as fats, vegetable oysters, cocoa butter, carnauba wax, spermacéti, petroleum jelly, silicone absorption excipients, such higher fats of emulsifying and / or water-soluble excipients, such as glycerin, propylene glycol, polyethylene glycol, cellulose derivatives, gum tragacanth, pectin, in addition to antibacterial agents ,

   preservatives, perfumes, essences, etc.



   The choice of excipients will be made on the basis of the desired type of formulation, according to the knowledge normally available, such as reported, for example, in "Remington's Pharmaceutical Sciences Handbook", Hack Publishing Co., U. S. A ..



   It is further evident that various other substances
 EMI2.2
 can be used in addition to or in place of those indicated above, and this is known to specialists in this pharmaceutical field. It should be understood that all of these formulations, although not being described in a particular way, normally remain within the scope of the present invention. In addition, the preparation of the compositions mentioned above is carried out according to techniques known in the art, for example by mechanical incorporation of the active principle
 EMI2.3
 in the base of the excipients, by fusion, emulsification, etc.

   The compositions which are the subject of the invention can. possibly contain other active ingredients, presenting a complementary or generally useful activity, such as antiseptics, analgesics, heparinoids, etc.



   The following Examples further illustrate the invention without, however, limiting it in any way.

 <Desc / Clms Page number 3>

 
 EMI3.1
 



  EXAMPLE 2% cream Composition 100 g of cream contain:
 EMI3.2
 Aeemetacin 2 g Excipients: Polyglycolic esters of fatty acids 18 g Propylene glycol 7 g Cetostearyl alcohol 3, 5 g Polyethylene glycol 1000, monocetyl ether 2 g
 EMI3.3
 Phenylethyl alcohol g
0.5 Sodium citrate 0.402 g Citric acid monohydrate 0.28 g Anallergic fragrance 0.1 g Pure water, sufficient to make 100 g EXAMPLE 2
 EMI3.4
 2% gel Composition Acemetacin 2 g Excipients:

   Carbopol 940 0, g Triethanolamine 1, OS g
8 Glycerin 2 g Isopropanol 30 g Coconut oil 0.04 g Lavender oil 0.04 g Eau de Cologne 0.07 g Demineralized water, sufficient to make 100 g

 <Desc / Clms Page number 4>

 
 EMI4.1
 EXAMPLE Gel Composition Acemetacin 2 g Carboxypolymethylene excipients 2 g p-Hydroxybenzoate of methyl 0, g p-Hydroxybenzoate of propyl g Essence of neroli 0, g Essence of lavender 0, g Alcohol 10 ml Demineralized water, quantity sufficient to make 100 g.


    

Claims (3)

3REVENDICATIONS t. Compositions topiques ä activité anti-inflammatoire, caractérisées en ce qu'elles contiennent, comme principe actif, de l'acémétacine et un véhicule pharmaceutiquement acceptable approprié.  3 CLAIMS t. Topical compositions with anti-inflammatory activity, characterized in that they contain, as active principle, acemetacin and an appropriate pharmaceutically acceptable vehicle. 2. Compositions suivant Ja revendication l, caractérisées en ce que le principe actif est utilisé ä raison de 0, 5 à 2 % en poids.  2. Compositions according to claim 1, characterized in that the active principle is used in an amount of 0.5 to 2% by weight. 3. Compositions suivant la revendication I, caractérisées en ce que le principe actif est utilisé en une quantité égale EMI5.1 à 2 % en poids.4. Compositions suivant l'une quelconque des revendicatiosn précédentes, qui se presentent sous la forme de crèmes, de gels, de pommades, de pätes, d'onguents.  3. Compositions according to claim I, characterized in that the active principle is used in an equal amount  EMI5.1  at 2% by weight. 4. Compositions according to any one of the preceding claims, which are in the form of creams, gels, ointments, pastes, ointments.
BE8700208A 1986-10-29 1987-03-04 Topical compositions antiinflammatory. BE1000147A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT22172/86A IT1197933B (en) 1986-10-29 1986-10-29 New topical antiinflammatory compsn.

Publications (1)

Publication Number Publication Date
BE1000147A3 true BE1000147A3 (en) 1988-05-17

Family

ID=11192568

Family Applications (1)

Application Number Title Priority Date Filing Date
BE8700208A BE1000147A3 (en) 1986-10-29 1987-03-04 Topical compositions antiinflammatory.

Country Status (2)

Country Link
BE (1) BE1000147A3 (en)
IT (1) IT1197933B (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966956A (en) * 1972-07-14 1976-06-29 Troponwerke Dinklage & Company [1-(P-Chlorobenzoyl)-5-methoxy-2-methyl-3-indole]acetoxyacetic acid and salts in treating inflammation
EP0055029A2 (en) * 1980-12-09 1982-06-30 Kowa Company, Ltd. Preparations for the treatment of dermatoses
EP0148391A2 (en) * 1983-12-10 1985-07-17 Bayer Ag Dispensing system for an active compound

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966956A (en) * 1972-07-14 1976-06-29 Troponwerke Dinklage & Company [1-(P-Chlorobenzoyl)-5-methoxy-2-methyl-3-indole]acetoxyacetic acid and salts in treating inflammation
EP0055029A2 (en) * 1980-12-09 1982-06-30 Kowa Company, Ltd. Preparations for the treatment of dermatoses
EP0148391A2 (en) * 1983-12-10 1985-07-17 Bayer Ag Dispensing system for an active compound

Also Published As

Publication number Publication date
IT8622172A0 (en) 1986-10-29
IT1197933B (en) 1988-12-21

Similar Documents

Publication Publication Date Title
EP0317846B1 (en) Pharmaceutical and cosmetical compositions based on benzoyl peroxide and lipophilic quaternary ammonium salicylates and their use, in particular in treating acne
EP0085579B1 (en) Topical pharmaceutical compositions
CA1339085C (en) Cosmetic and pharmaceutical compositions containing benzoyl peroxide andquaternary ammonium salts thereof
US5145686A (en) Topical pharmaceutical compositions
WO1999013857A1 (en) Aqueous solutions of salicylic acid derivatives
BE898268A (en) New anti-acne composition based on benzoyl peroxide and at least one other active ingredient.
HU208253B (en) Nitroglycerine pumping spray
EP0862423A1 (en) Pharmaceutical composition for oral delivery
LU83073A1 (en) NOVEL ANTI-MICROBIAL COMPOSITIONS FOR THE TOPICAL TREATMENT OF VULGAR ACNE
EP0055635A1 (en) Pharmaceutical composition with acetylsalicylic acid in gel form
FR2490492A1 (en) Compsns. for treating cellulitis - contg. xanthine base and seaweed extract
FR2581310A1 (en) THERAPEUTIC COMPOSITION COMPRISING A-LINOLENIC ACID AND A COMPOUND CAPABLE OF PROMOTING ACID PASSAGE THROUGH CELL MEMBRANE AND PLANT EXTRACT COMPRISING ACID AND COMPOUND
JPS6094913A (en) Local agent and pack containing tar and fatty acid and use
FR2585575A1 (en) Pharmaceutical compositions having keratolytic activity in the form of an aqueous alcoholic gel containing salicylic acid
BE1000147A3 (en) Topical compositions antiinflammatory.
FR2462909A1 (en) DERMATOLOGICAL COMPOSITION BASED ON DERIVATIVES OF APOVINCAMINIC ACID OR APOVINCIN AND ITS DERIVATIVES FOR THE TREATMENT OF SKIN DISEASES, ACCOMPANIED BY CELLULAR PROLIFERATION, SUCH AS PSORIASIS
FR2646603A1 (en) CLEANING COMPOSITION
CA1289884C (en) ANTI-INFLAMMATORY MEDICAMENT HAVING A SYNERGISTIC ACTIVITY AND COMPRISING A CORTICOSTEROID AND A .beta.-AGONIST
FR2556968A1 (en) Topical dermatological composition for the treatment of acne, based on a lipid fraction extracted from Serenoa repens fruits
BE1000153A4 (en) Anti-acne STABLE COMPOSITION BASED ERYTHROMYCIN.
CA2684126A1 (en) Antifungal foam containing ciclopiroxolamine and zinc pyrithione, and medical and cosmetic applications thereof
FR2541895A1 (en) Deodorant and anti-perspirant composition based on triterpenic acid
FR2760363A1 (en) Composition for topical treatment of skin disorders
EP0865289B1 (en) Arctium majus compositions
JPH05503295A (en) Composition for topical treatment of psoriasis

Legal Events

Date Code Title Description
RE Patent lapsed

Owner name: ISTITUTO BIOCHIMICO SPERIMENTALE IBIS S.P.A.

Effective date: 19890331